Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic

American Journal of Health-System Pharmacy

Volumn 64, Issue 24, 2007, Pages 2574-2578

  March, Kristi ^a   Mak, May ^b   Louie, Stan G ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ambulatory care; Antiretroviral agents; Dosage; HIV infections; Interventions; Patient information; Pharmaceutical services; Pharmacists; Quality of life; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST ATTITUDE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANK SUM TEST; STUDENT T TEST; VIRUS LOAD;

EID: 37249008125     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070048     Document Type: Article

References (31)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-60.
2. Reiter GS. Comprehensive clinical care: managing HIV as a chronic illness. AIDS Clin Care. 2000; 12:13-21.
3. Foisy MM, Tseng A, Blaikie N. Pharmacists' provision of continuity of care to patients with human immunodeficiency virus infection. Am J Health-Syst Pharm. 1996; 53:1013-7.
4. Colombo J. Establishing pharmaceutical care services in an HIV clinic. J Am Pharm Assoc. 1997; NS37:581-92.
5. Fung HB, Pecini RA, Brown ST. HIV pharmacotherapy clinic. Am J Health-Syst Pharm. 1998; 55:955-6. Letter.
6. Warnock AC, Rimland D. The provision of pharmaceutical care in a Veterans' Affairs medical center outpatient HIV clinic. Hosp Pharm. 1994; 29:114-6.
7. Walji N, Beardsell A, Brown G. Pharmacist's activities in monitoring zidovudine therapy in an AIDS clinic. Can J Hosp Pharm. 1992; 45:29-31.
8. Hicks AR. Helping HIV-infected patients at the clinic. Am J Health-Syst Pharm. 1998; 55:661-3.
9. Wong RJ, Volberding PA. Providing clinical pharmacy services in an AIDS-oncology ambulatory care clinic. Am J Hosp Pharm. 1988; 45:2351-4.
10. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
11. Murphy DA, Wilson CM, Durako SJ et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001; 13:27-40.
12. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000; 30(suppl 2):S171-6.
13. Mehta S, Moore R, Graham N. Potential factors affecting adherence with HIV therapy. AIDS. 1997; 11:1665-70.
14. Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. AIDS. 2002; 16:737-45.
15. Mocroft A, Youle M, Moore A et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001; 15:185-94.
16. D'Arminio Monforte A, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000; 14:499-507.
17. AIDS info. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. www.aidsinfo.nih.gov/guidelines (accessed 2007 Oct 3).
18. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31:1341-6.
19. Ware JE, Dewey KM, Gandek B. How to score and interpret single-item health status measures: a manual for the users of the SF-8 health survey. Lincoln, RI: QualityMetric, Inc.; 2001.
20. Young YL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law. 1986; 14:105-22.
21. Coons SJ, Sheanhan SL, Martin SS et al. Predictors of medication noncompliance in a sample of older adults. Clin Ther. 1994; 16:110-7.
22. Draine J, Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population. J Nerv Ment Dis. 1994; 182:50-4.
23. Carney R, Freedland K, Eisen S et al. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995; 14:88-90.
24. Pugh R. An association between hostility and poor adherence to treatment in patients suffering from depression. Br J Med Psychol. 1983; 56(pt. 2):205-8.
25. Hadler S, Judson F, O'Malley P. Outcome of hepatitis B virus infection in homosexual men and its relation to prior HIV infection. J Infect Dis. 1991; 163:454-9.
26. Thio C, Netski D, Myung J et al. Changes in hepatitis B DNA levels with acute HIV infection. Clin Infect Dis. 2004; 38:1024-9.
27. Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004; 18:1-12.
28. Bonacini M, Louie S, Bzowej N et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004; 18:2039-46.
29. Low-Beer S, Yip B, O'Shaughnessy MV et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000; 23:360-1. Letter.
30. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000; 5:41-8.
31. Hilts AE, Fish DN. Antiretroviral dosing in patients with organ dysfunction. AIDS Read. 1998; 8:179-84.